[*] CONFIDENTIAL TREATMENT REQUESTED. THE REDACTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
Effective as of April 1, 1998 ("Effective Date"), THE BOARD OF TRUSTEES OF THE LELAND
STANFORD JUNIOR UNIVERSITY, a body having corporate powers under the laws of the State of
California ("STANFORD"), and THESEUS MEDICAL IMAGING, a Delaware corporation having a principal
place of business at One Financial Center, Boston, MA 02111 ("LICENSEE"), agree as follows:
1.1 STANFORD and University of Washington ("UW") has an assignment to "Imaging of Programmed Cell
Death (Apoptosis) Using Technetium 99m Radiolabeled Annexin V" from the laboratories of Drs. H. William
Strauss and Francis Blankenberg here at STANFORD and Dr. John Tait at UW ("Invention[s]"), as described in
Stanford Docket S96-214, and any Licensed Patent(s), as hereinafter defined, which may issue to such Invention
1.2 STANFORD has certain technical data and information as herein defined ("Technology") pertaining to
1.3 STANFORD desires to have the Technology and Invention(s) perfected and marketed at the earliest
possible time in order Out products resulting therefrom may be available for public use and benefit.
1.4 LICENSEE desires a license under said Technology, Invention(s), and Licensed Patent(s) to develop,
manufacture, use, and sell Licensed Product(s) in the field of use of Human and Veterinary Diagnosis.
1.5 The Technology and Invention(s) were made in the course of research supported by the National Institutes of
Health and the Child Health Research Fund.
1.6 STANFORD has entered into an agreement with UW granting STANFORD authority to act on behalf of
UW in connection with the licensing of UWs rights in the Inventions and Technology.
1.7 STANFORD asserts that it has the right to enter into this license agreement for the licensing of the rights to
Invention(s) and Technology.
2.1 "Licensed Patent(s)" means any Letters Pate